Heparin-Conjugated Pluronic Nanogels as Multi-Drug Nanocarriers for Combination Chemotherapy
- Heparin-Conjugated Pluronic Nanogels as Multi-Drug Nanocarriers for Combination Chemotherapy
- 정윤기; 장지영; 최종훈; 한동근; 박기동
- heparin; Pluronic; combination chemotherapy; DNase; paclitaxel; nanocarrier
- Issue Date
- Molecular pharmaceutics
- VOL 10, NO 2, 685-693
- Combination chemotherapy using more than two therapeutic agents with different modes of action is a promising strategy that can be used to enhance the therapeutic efficacy of cancer
treatment, even though it is a complicated treatment modality. The
aim of this study was to investigate how a novel multidrug nanocarrier
is effective for combination chemotherapy in vitro and, more
specifically, whether combined agents with different modes of action
and physicochemical properties show synergistic cytotoxicity with the
use of this nanocarrier. A heparin−Pluronic (Hep−Pr) nanogel
encapsulating both paclitaxel and DNase was shown to be efficient for
intracellular delivery with respect to size, encapsulation efficiency, and intracellular uptake/fates. As a result of these properties, a
Hep−Pr nanogel combined with paclitaxel and DNase exhibited a dose-dependent synergistic cytotoxicity compared to single
drug and free-drug treatments, whose combination indices were 0.93 and 0.45 at higher concentrations (250 and 500 μg/mL).
Therefore, Hep−Pr nanogels have the potential to deliver multitherapeutic agents with different characteristics and thereby
enhance the therapeutic efficacy of combination cancer chemotherapy.
- Appears in Collections:
- KIST Publication > Article
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.